Chapter from the book *Type 1 Diabetes - Complications, Pathogenesis, and Alternative Treatments*

Downloaded from: http://www.intechopen.com/books/type-1-diabetes-complications-pathogenesis-and-alternative-treatments
Lipid Disorders in Type 1 Diabetes

Bruno Vergès
Service Endocrinologie, Diabétologie et Maladies Métaboliques
Dijon University Hospital
France

1. Introduction
Cardiovascular disease is the major cause of death in persons with type 1 diabetes (Libby et al., 2005). Dyslipidemia has been shown to be a significant coronary heart disease risk factor in type 1 diabetes (Soedamah-Muthu et al., 2004; Grauslund et al., 2010). Thus, it seems important to pay attention to lipid abnormalities, in patients with type 1 diabetes, in order to reduce cardiovascular disease in this population. Patients with type 1 diabetes show lipid disorders, mostly qualitative abnormalities of lipoproteins, which may promote atherogenesis. The pathophysiology of these lipid abnormalities is not totally explained, but hyperglycemia and peripheral hyperinsulinemia, due to the subcutaneous route of insulin administration, are likely to play a role. After a brief review of lipoprotein metabolism and some information on the role of insulin on lipid metabolism, quantitative abnormalities then qualitative abnormalities of lipoproteins, in type 1 diabetes, will be discussed.

2. Brief review of lipoprotein metabolism
Lipoproteins, which transport non-water soluble cholesterol and triglycerides in plasma, are spherical particles composed of a central core of non-polar lipids (cholesterol esters, triglycerides) and a surface monolayer of phospholipids, free cholesterol and apolipoproteins. Lipoproteins are generally classified according to their density as chylomicron, Very Low Density Lipoprotein (VLDL), Intermediate Density Lipoprotein (IDL), Low Density Lipoprotein (LDL) and High Density Lipoprotein (HDL). An overview of lipoprotein metabolism is shown in Figure 1.

2.1 Chylomicrons
Chylomicrons, the largest lipoprotein particles, are responsible for the transport of dietary triglycerides and cholesterol. Chylomicrons are composed of triglycerides (85-90%), cholesterol esters, phospholipids and apolipoproteins (mainly apoB48 but also apoA-I and apoA-IV). The formation of chylomicrons takes place in the enterocytes, and the process associating the lipid components (triglycerides, cholesterol esters, phospholipids) and the apoB48 is performed by the MTP (Microsomal Tranfer Protein). Chylomicrons are secreted into the lymphatic circulation before entering the bloodstream. In plasma, triglycerides of chylomicrons are hydrolyzed by the lipoprotein lipase leading to the formation of smaller, triglyceride-poorer particles known as chylomicron-remnants. Chylomicron-remnants are
cleared by the liver through LDL B/E receptor or LRP receptor (LDL-receptor related protein).

![Diagram of human lipoprotein metabolism](image)

**VLDL**: Very Low Density Lipoprotein; **IDL**: Intermediate Density Lipoprotein, **LDL**: Low Density Lipoprotein; **HDL**: High Density Lipoprotein; **LPL**: LipoProtein Lipase; **HL**: Hepatic Lipase; **CETP**: Cholesteryl Ester Transfer Protein; **LCAT**: Lecithin-Cholesterol Acyl Transferase; **FFA**: Free Fatty Acids; **B/E rec.**: B/E receptor (LDL receptor); **TG**: Triglycerides; **CE**: Cholesterol Esters; **ABCA1**: ATP Binding Cassette A1 transporter.

Fig. 1. Human lipoprotein metabolism.

### 2.2 VLDLs and IDLs

VLDL particles, which are secreted by the liver, consist of endogenous triglycerides (55% to 65%), cholesterol, phospholipids and apolipoproteins (apoB100 as well as apoCs and apoE). In the hepatocyte, the formation of VLDL occurs in two major steps. In the first step, which takes place in the rough endoplasmic reticulum, apoB is co-translationally and post-translationally lipidated by the MTP (Microsomal Tranfer Protein). MTP transfers lipids (mainly triglycerides but also cholesterol esters and phospholipids) to apoB. This first step leads to the formation of pre-VLDL (Olofsson et al., 2000). In the second step, pre-VLDL is converted to VLDL in the smooth membrane compartment. This step is driven by ADP ribosylation factor-1 (ARF-1) and its activation of phospholipase D, needed for the formation of VLDL from pre-VLDL (Olofsson, 2000).

In plasma, triglycerides of VLDLs are hydrolyzed by the lipoprotein lipase. As VLDLs become progressively depleted in triglycerides, a portion of the surface including phospholipids and apolipoproteins C and E is transferred to HDLs. This metabolic cascade leads to the formation of IDL particles, which are either cleared by the liver through LDL B/E receptor or further metabolized to form LDLs. The enzyme, hepatic lipase, which has
both triglyceride lipase and phospholipase activities, is involved in this metabolic process generating LDL particles from IDLs.

2.3 LDLs
LDL is the final product of the VLDL-IDL-LDL cascade. LDL is the main cholesterol-bearing lipoprotein in plasma. Each LDL particle contains one molecule of apoB100, which plays an important role in LDL metabolism, particularly recognition of its dedicated LDL B/E receptor. Clearance of LDL is mediated by the LDL B/E receptor. Seventy percent of LDL B/E receptors are located on hepatic cells and 30% on the other cells of the body.

2.4 HDLs
HDL particles are secreted by the hepatocytes as small lipid-poor lipoproteins, containing mostly apoA-I, which receive, in the circulation, phospholipids, apoCs and apoE from chylomicrons and VLDLs. Nascent or lipid-poor HDLs get from peripheral cells free cholesterol and phospholipids through ABCA1 transporter (ATP Binding Cassette A1 transporter), allowing the transport of free cholesterol and phospholipids from the cell cytoplasm into the HDL particles (Oram & Lawn, 2001). Within HDL particles, free cholesterol is esterified by LCAT (Lecithin Cholesterol AcylTransferase) leading to the formation of HDL3 particles. The fusion of 2 HDL3 particles, which is promoted by PLTP (PhosphoLipid Transfer Protein), leads to the formation of one larger size HDL2 particle. HDL2 lipoproteins, rich in cholesterol ester, are degraded by the hepatic lipase and the endothelial lipase, leading to the formation of HDL remnant particles that are cleared by the liver after recognition by SR-B1 receptor (Scavenger Receptor class B type 1) (Jian et al., 1998).

2.5 Lipid transfer proteins
Lipoprotein metabolism is largely influenced by lipid transfer proteins. Among these, two play an important role: CETP (Cholesteryl Ester Transfer Protein) and PLTP (PhosphoLipid Transfer Protein). CETP facilitates the transfer of triglycerides from triglyceride-rich lipoproteins (mainly VLDLs) toward HDLs and LDLs and the reciprocal transfer of cholesteryl esters from HDLs and LDLs toward VLDLs (Lagrost, 1994). PLTP facilitates the transfer of phospholipids and α-tocopherol between lipoproteins. PLTP is also involved in the formation of HDL2 lipoproteins from HDL3 particles (Lagrost et al., 1998). Any modification of CETP or PLTP activities is likely to promote significant qualitative abnormalities of lipoproteins.

3. Insulin and lipoprotein metabolism
Insulin plays a central role in the regulation of lipid metabolism (Vergès, 2001). The main sites of action of insulin on lipoprotein metabolism are shown in Figure 2. In adipose tissue, insulin inhibits the hormone-sensitive lipase. Thus, insulin has an anti-lipolytic action, promoting storage of triglycerides in the adipocytes and reducing release of free fatty acids from adipose tissue in the circulation.

Insulin inhibits VLDL production from the liver. In normal subjects, it has been shown that insulin induces a 67% decrease of VLDL-triglyceride production and a 52% decrease of VLDL-apoB production (Lewis et al., 1993; Malmström et al., 1998). Insulin reduces VLDL production by diminishing circulating free fatty acids (due to its antilipolytic effect), which
are substrates for VLDL, but also by a direct inhibitory effect in the hepatocyte (Malmström et al., 1998). Insulin is a potent activator of lipoprotein lipase (LPL), promoting the catabolism of triglyceride-rich lipoproteins and reducing, as a consequence, plasma triglyceride level. Insulin not only enhances LPL activity (Brunzell et al., 1998), but has also a direct positive effect on LPL gene, promoting LPL synthesis (Fried et al., 1993). Insulin promotes the clearance of LDL, by increasing LDL B/E receptor expression and activity (Chait et al., 1979, Mazzone et al., 1984). Insulin acts also on HDL metabolism by activating LCAT and hepatic lipase activities (Ruotolo et al., 1994).

Fig. 2. Main effects of insulin on lipoprotein metabolism.

4. Quantitative lipid abnormalities in type 1 diabetes

4.1 Untreated (diabetic ketoacidosis) type 1 diabetes
In type 1 diabetic patients with diabetic ketoacidosis, quantitative lipid abnormalities are observed, due to insulin deficiency.
Triglyceride-rich lipoproteins (chylomicrons, VLDLs) are increased leading to hypertriglyceridemia. This is mainly due to decreased lipoprotein lipase activity (Vergès, 2001; Dullaart, 1995). Diabetic ketoacidosis is a situation of severe insulin deficiency with reduced lipoprotein lipase activity as a consequence, because insulin usually stimulates its activity. Decreased lipoprotein lipase activity leads to profound reduction of triglyceride-rich lipoprotein catabolism (Taskinen, 1987). In this condition of severe insulin deficiency, reduced catabolism of triglyceride-rich lipoproteins is, by far, the main factor involved in hypertriglyceridemia. This hypertriglyceridemia resolves rapidly after well titrated insulin therapy (Weidman et al., 1982).

LDL-cholesterol is decreased during diabetic ketoacidosis (Weidman et al., 1982). This fall in plasma LDL-cholesterol level is the direct consequence of the reduction of triglyceride-rich lipoprotein catabolism, due to decreased lipoprotein lipase activity (see above).

In diabetic ketoacidosis, HDL-cholesterol level is significantly decreased (Weidman et al., 1982). This is a consequence of hypertriglyceridemia observed in this condition. Indeed, the augmented level of plasma triglyceride-rich lipoproteins drives, through CETP, the transfer of triglycerides from triglyceride-rich lipoproteins to HDLs leading to the formation of triglyceride-rich HDL particles. HDLs enriched in triglycerides become very good substrate for hepatic lipase, leading to increase their catabolism and, thus, to decrease plasma HDL-cholesterol level. This low HDL-cholesterol condition resolves rapidly after well titrated insulin therapy (Weidman et al., 1982).

4.2 Treated type 1 diabetes

Patients with treated type 1 diabetes may show quantitative lipid disorders. In a prospective study performed in 895 young subjects with type 1 diabetes, 20.1% had plasma triglycerides above 1.7 mmol/l, 9.6% had LDL-cholesterol above 3.4 mmol/l and 25.9% had non-HDL cholesterol above 3.4 mmol/l (Marcovecchio et al., 2009). It has been shown that abnormal lipid levels, in type 1 diabetes, predict worse cardiovascular outcomes (Soedamah-Muthu et al., 2004). HbA1c has been shown to be independently correlated with LDL-cholesterol, non-HDL cholesterol and triglyceride levels, indicating that these disorders were mostly observed in patients with poor glycemic control (Marcovecchio et al., 2009). In a British follow-up study of 229 children with type 1 diabetes, LDL cholesterol and non-HDL cholesterol values increased with duration of diabetes (Edge et al., 2008). In that study, total cholesterol, triglycerides and non-HDL cholesterol were positively correlated with HbA1c and around 10% of the patients had lipid values outside recommendations (Edge et al., 2008). In a large study performed in 29 979 patients with type 1 diabetes, multivariate analyses showed a significant positive association between HbA1c and total cholesterol (p<0.0001), LDL cholesterol (p<0.0001) and a significant negative association between HbA1c and HDL cholesterol (p<0.0001) (Schwab et al., 2009). In the Diabetes Control and Complications Trial (DCCT), HbA1c correlated positively with total cholesterol, LDL-cholesterol and triglycerides at baseline (The DCCT Research Group, 1992). Data from the Coronary Artery Calcification in type 1 diabetes (CACTI) study, which examined 652 patients with type 1 diabetes, have shown, in patients not using hypolipidemic agents, that a higher HbA1c was associated with significantly higher levels of total cholesterol, triglycerides, LDL cholesterol and non-HDL cholesterol (Maahs et al., 2010). In that study, 1% change in HbA1c was associated with an increase of 0.101 mmol/l (4 mg/dl) for total cholesterol, of 0.052 mmol/l (4.5 mg/dl) for triglycerides, of 0.103 mmol/l (4 mg/dl) for LDL cholesterol and of 0.129 mmol/l (5 mg/dl) for non-HDL cholesterol (Maahs et al.,
In a recent study, performed in 512 young patients with type 1 diabetes and in 188 healthy age-matched controls, patients with suboptimal control (HbA1c ≥ 7.5%) had much more lipid quantitative disorders than patients with optimal control (HbA1c<7.5%) (Guy et al., 2009). All these data suggest that quantitative lipid abnormalities are more frequent, when type 1 diabetes is not well controlled.

In addition, some patients with type 1 diabetes may have insulin resistance, in situation of abdominal obesity and/or family history of type 2 diabetes. Such patients have been shown to have greater dyslipidemia (Purnell et al., 2003). In a recent study performed in 60 young type 1 diabetic patients and 40 adults with type 1 diabetes, it has been shown, using hyperinsulinemic clamp studies, that lower glucose infusion (more insulin resistance) was associated with lower levels of HDL cholesterol in youths with type 1 diabetes and with higher levels of triglycerides and higher triglyceride/HDL ratio in both youths and adults (Maahs et al., 2011). These data indicate that insulin resistance may be an additional factor that could induce quantitative lipid abnormalities in some type 1 diabetic patients with a background of insulin resistance (abdominal obesity, family history of type 2 diabetes). In this chapter we will consider only the typical situation of type 1 diabetes without insulin resistance.

4.2.1 Treated type 1 diabetes with poor or suboptimal glycemic control

In case of poor or suboptimal control, patients with type 1 diabetes may show increased plasma triglyceride levels (Dullaart,1995). This hypertriglyceridemia is due to increased production of VLDL, promoted by elevated circulating free fatty acids secondary to the relative insulin deficiency (Nikkilä & Kekki, 1973).

Type 1 diabetic patients with poor or suboptimal glycemic control show increased LDL-cholesterol levels as compared to non–diabetic individuals and type 1 diabetic patients with optimal glycemic control (Dullaart, 1995; Guy et al., 2009). Indeed, in this condition, VLDL production is increased (see above), when catabolism of triglyceride-rich lipoproteins is not importantly decreased, which leads to increase LDL production (Dullaart, 1995).

4.2.2 Treated type 1 diabetes with optimal glycemic control

In well controlled type 1 diabetes, the lipid profile is totally different than in poorly controlled type 1 diabetes (Dullaart, 1995; Nikkilä & Kekki, 1973).

Plasma triglycerides are normal or slightly decreased (Dullaart, 1995; Nikkilä & Kekki, 1973). This slight decrease in plasma triglycerides may be observed with intense insulin therapy because of increased down control of VLDL production by augmented plasma insulin levels as a consequence of the subcutaneous route of insulin delivery (Dashti & Wolfbauer, 1987; Taskinen, 1992). Furthermore, in patients with well controlled type 1 diabetes, peripheral hyperinsulinemia has been shown to be associated with increased lipoprotein lipase activity that could be an additional factor responsible for decreased plasma triglycerides (Nikkilä et al., 1977).

Plasma LDL-cholesterol level is normal or slightly decreased (Winocour et al., 1986). This slight decrease in plasma LDL-cholesterol may be observed with intense insulin therapy as a consequence of decreased VLDL production by peripheral hyperinsulinemia (see above).

Plasma HDL-cholesterol level is normal or slightly increased in well controlled type 1 diabetic patients (Dullaart, 1995). Some studies have shown an increase in HDL subfraction 2 (Eckel et al., 1981; Kahri et al., 1993), when others have found an increase in HDL...
subfraction 3 (Winocour et al., 1986). It has also been reported that elevation of HDL in type 1 diabetic patients with good glycemic control was caused by an increase of HDL particles containing only apoA-I (LpA-I) (Kahri et al., 1993). This increase in plasma HDL-cholesterol could be the consequence of the elevated Lipoprotein Lipase/Hepatic Lipase ratio that is observed in patients with well controlled type 1 diabetes (increased Lipoprotein Lipase activity and normal Hepatic Lipase activity) (Kahri et al., 1993). The increased Lipoprotein Lipase activity observed in these patients is likely to be due to peripheral hyperinsulinemia as a consequence of the subcutaneous route of insulin administration (Kahri et al., 1993).

4.2.3 Subcutaneous insulin therapy versus intraperitoneal insulin therapy

Intensive subcutaneous insulin therapy results in normalization of plasma glucose, but at the expense of peripheral hyperinsulinemia, which is likely to modify lipoprotein metabolism (as discussed above). Implantable insulin pumps with intraperitoneal insulin administration mimic the physiologic route of insulin delivery and are likely to restore the normal portal-peripheral insulin gradient. For this reason, several studies have been performed to analyze the modification of lipoprotein metabolism after replacement of subcutaneous insulin therapy by intraperitoneal insulin therapy. Plasma triglycerides have been found increased in one study (Selam et al., 1989) and unchanged in three other studies (Bagdade & Dunn, 1996; Ruotolo et al., 1994; Duvillard et al., 2005). Total cholesterol and apoB were found unchanged (Bagdade & Dunn, 1996; Ruotolo et al., 1994; Duvillard et al., 2005). HDL-cholesterol has been found decreased (Selam et al., 1989) or not modified (Bagdade & Dunn, 1996; Ruotolo et al., 1994; Duvillard et al., 2007). The discrepancies of these studies that may be due to confounding factors such as degree of glycemic control and peripheral insulin levels during subcutaneous insulin therapy. Further studies are needed to clearly evaluate the effect of intraperitoneal insulin administration on lipoprotein metabolism.

4.2.4 Type 1 diabetes with nephropathy

In type 1 diabetic patients with nephropathy and overt albuminuria, elevated plasma levels of total cholesterol, triglycerides and LDL-cholesterol are observed whereas HDL-cholesterol is decreased due to a fall in HDL_{2} (Dullaart, 1995; Taskinen, 1992; Jensen et al., 1987). In the EURODIAB IDDM Complications study, macroalbuminuria was associated with significantly increased plasma triglycerides, cholesterol, LDL-cholesterol and LDL/HDL ratio in both sexes and decreased HDL-cholesterol in women (Mattock et al., 2001).

Some quantitative lipid modifications are also observed in type 1 diabetic patients with microalbuminuria. Microalbuminuric patients compared with normoalbuminuric patients show increased plasma apoB (Jones et al., 1989, Dullaart et al, 1989a; Jay et al., 1991), LDL cholesterol (Jones et al., 1989, Dullaart et al, 1989a) and apoB/apoA1 ratio (Dullaart et al, 1989a; Jay et al., 1991). A positive correlation has been found between urinary albumin excretion rate and plasma apoB and apoB/apoA1 ratio (Dullaart et al, 1989a). In the EURODIAB IDDM Complications study, microalbuminuria was associated with increased plasma triglycerides (Mattock et al., 2001). In a prospective study performed in 895 young subjects with type 1 diabetes, total cholesterol and non-HDL cholesterol were independently related to longitudinal changes in albumin-to-creatinine ratio (Marcovecchio et al., 2009). The mechanisms responsible for these lipoprotein abnormalities in type 1 diabetic patients with microalbuminuria remain unclear.
Moreover, serum lipids have been shown to be associated with the progression of nephropathy in type 1 diabetes. In a prospective study performed in 152 patients with type 1 diabetes followed for 8-9 years, LDL-cholesterol was an independent factor associated with progression of nephropathy (Thomas et al., 2006).

5. Qualitative lipid abnormalities in type 1 diabetes

Several qualitative abnormalities of lipoproteins are observed in patients with type 1 diabetes, even in those with good metabolic control, who do not have significant quantitative lipid changes. These qualitative lipid abnormalities are not totally reversed by optimal glycemic control and are likely to be atherogenic.

5.1 VLDLs

VLDLs from patients with type 1 diabetes are frequently enriched in esterified cholesterol at the expense of triglycerides leading to an increased VLDL cholesterol/triglyceride ratio (Rivellese et al., 1988; Bagdade et al., 1991a). It has been suggested that this compositional changes may be due to increased cholesteryl ester transfer between lipoproteins (Bagdade et al., 1991a). It has been shown that the VLDL cholesterol/triglyceride ratio was significantly reduced with intraperitoneal insulin therapy (Dunn, 1992). Furthermore, the free cholesterol /lecithin ratio within the peripheral layer of VLDL particles is increased (Dullaart, 1995; Bagdade et al., 1991a). Such increase in the free cholesterol /lecithin ratio within the peripheral layer of lipoproteins has been shown to raise the risk for cardiovascular events possibly by reducing fluidity and stability of lipoproteins (Kuksis, 1982). Moreover, VLDLs from patients with type 1 diabetes have been shown, in vitro, to induce abnormal response of cellular cholesterol metabolism in human macrophages (Klein et al., 1989).

5.2 LDLs

In patients with type 1 diabetes, LDLs are often enriched in triglycerides and increased number of small dense LDL particles is observed (Guy et al., 2009; Lahdenperä et al., 1994; James & Pometta, 1990; Skyrme-Jones et al., 2000). In a study performed in 2657 patients with type 1 diabetes, it has been shown that dense LDL increased with HbA1c with buoyant LDL shifting toward dense LDL for HbA1c values above 8% (Albers et al., 2008). It has been shown that the presence of small dense LDL particles is associated with increased cardiovascular risk (Austin et al., 1990). Many data indicate that small dense LDL particles have atherogenic properties. Indeed, small dense LDL particles have reduced affinity for the LDL B/E receptor and are preferentially taken up by macrophages, through the scavenger receptor, leading to the formation of foam cells. Small dense LDL particles have higher affinity for intimal proteoglycans than large LDL particles which may favor the penetration of LDL particles into the arterial wall (Chapman et al., 1998). It has been shown that subjects with small dense LDL particles show an impaired response to endothelium dependent vasodilator acetylcholine (Vakkilainen et al., 2000). Moreover, small dense LDL particles show an increased susceptibility to oxidation (Tribble et al., 1992). A reduction of the proportion of small dense LDL particles has been reported after optimization of glycemic control in patients with type 1 diabetes (Caixàs et al., 1997).

The free cholesterol /lecithin ratio within the peripheral layer of LDL particles is increased (Dullaart, 1995; Bagdade et al., 1991a). In patients with type 1 diabetes, glycation of ApoB
occurs within LDL in parallel with plasma hyperglycemia. It has been shown that apoB glycation reduces significantly LDL binding to the B/E receptor even when apoB glycation is moderate (Witztum et al., 1982; Steinbrecher et al., 1984). Furthermore, glycated LDLs are preferentially taken up by macrophages through the scavenger receptor, leading to the formation of foam cells in the arterial wall. In patients with type 1 diabetes, advanced glycation end products-modified LDL have been shown to be positively associated with increased intima media thickness (IMT) (Lopes-Virella et al., 2011). Moreover, patients with type 1 diabetes may show an increased oxidation of LDL which is promoted by glycemic excursions (de Castro et al., 2005). Increased urinary excretion of malondialdehyde, reflecting enhanced lipid peroxidation, has been reported in patients with type 1 diabetes (Hoeldtke et al., 2009). Oxidative modification of LDL results in rapid uptake by macrophages, leading to foam cell formation. Oxidized LDLs produce chemotactic effects on monocytes by increasing the synthesis of adhesion molecules, such as ICAM-1 (intercellular adhesion Molecule 1) by endothelial cells. Oxidized LDLs stimulate the formation by macrophages of cytokines, such as TNFα or IL1, which amplify the inflammatory atherosclerotic process. It has recently been shown that oxidized LDL particles were significantly associated with progression and increased levels of IMT in type 1 diabetes (de Castro et al., 2005).

5.3 HDLs
HDL particles from patients with type 1 diabetes are often enriched in triglycerides (Dullaart, 1995; Bagdade et al., 1991a). This modification has been attributed to increased cholesteryl ester transfer between lipoproteins (Bagdade et al., 1991a). In HDL particles from patients with type 1 diabetes, sphingomyelin/lecithin ratio within the peripheral layer is augmented, which may increase HDL rigidity (Bagdade & Subbaiah, 1989). These alterations are not totally reversed after achievement of optimal glycemic control (Bagdade et al., 1991b). ApoA-I within HDL is glycated in patients with type 1 diabetes, which may impair the HDL-mediated reverse cholesterol pathway. Indeed, it has been shown that HDL particles containing glycated apoA-I were less effective to promote cholesterol efflux from the cells (Fievet et al., 1992).

In addition to their role in the reverse cholesterol pathway, HDLs have anti-oxidative, anti-inflammatory, anti-thrombotic and vasorelaxant properties, potentially anti-atherogenic (Link et al., 2007). Some of these properties have been shown to be reduced in patients with type 1 diabetes. Indeed, a significant reduction of the activity of paraoxonase, an anti-oxidative enzyme associated with HDLs, is observed in patients with type 1 diabetes (Boemi et al., 2001; Ferretti et al., 2004). As a consequence, HDLs from patients with type 1 diabetes protect less efficiently erythrocyte membranes and LDL particles against oxidative damage than HDLs from normal individuals (Boemi et al., 2001; Ferretti et al., 2004). Furthermore, using rabbit aorta rings, it has been shown that HDL from patients with type 1 diabetes are no more able to prevent the endothelium dependent vasoconstriction induced by oxidized LDL, whereas HDL from normal individuals can prevent it (Perségol et al., 2007).

5.4 Lipid transfer proteins
In some studies, an increased cholesteryl ester transfer between lipoproteins (Bagdade et al., 1991a; Bagdade et al., 1994) or an augmented activity of CETP (Colhoun et al., 2001) have been found in normolipidemic patients with type 1 diabetes. In some other studies, increased CETP activity has been reported only in type 1 diabetic patients that smoke or
those having microalbuminuria (Dullaart et al., 1989b; Dullaart et al., 1991). This augmented CETP activity may explain the increase in free cholesterol/triglycerides ratio within VLDL and its decrease within HDL. Some studies have shown a positive correlation between CETP activity and hyperglycemia (Ritter & Bagdade, 1994; Chang et al., 2001). However, the main factor which is likely to be responsible for increased CETP activity, in type 1 diabetes, could be peripheral hyperinsulinemia secondary to the subcutaneous route of insulin administration. Indeed, peripheral hyperinsulinemia has been shown to be responsible for increased lipoprotein lipase activity in patients with type 1 diabetes (Nikkilä et al., 1977) and it has been reported that lipoprotein lipase, in presence of VLDL, enhances CETP activity (Sammett & Tall, 1985; Pruneta et al., 1999). Moreover, it has been shown, in patients with type 1 diabetes, that the increase in both lipoprotein lipase and CETP activities was abolished when insulin was administrated intraperitoneously with implantable insulin pumps, mimicking the physiologic portal route or after pancreatic graft (Bagdade et al., 1994; Bagdade et al., 1996).

Increased PLTP activity has been reported in patients with type 1 diabetes (Colhoun et al., 2001). In this study, PLTP activity was positively correlated with CETP activity, LDL-cholesterol and HDL-cholesterol (Colhoun et al., 2001). The reasons and consequences of this increased PLTP activity are not clear.

6. Conclusion

In conclusion, quantitative lipid abnormalities are observed in patients with poorly controlled type 1 diabetes (increased triglyceride and LDL-cholesterol levels) or with micro- or macroalbuminuria (increased triglycerides and LDL-cholesterol, decreased HDL-cholesterol). Patient with optimally controlled type 1 diabetes show normal or slightly decreased triglycerides and LDL-cholesterol levels and sometimes increased HDL-cholesterol levels. Qualitative abnormalities of lipoproteins are observed in patients with type 1 diabetes, even in good glycemic control. These abnormalities are not fully explained by hyperglycemia and may partly be due to peripheral hyperinsulinemia associated with the subcutaneous route of insulin administration. The exact consequences of these qualitative lipid changes on the development of cardiovascular disease in type 1 diabetes are still unknown.

7. References

Albers JJ, Marcovina SM, Imperatore G, Snively BM, Stafford J, Fujimoto WY, Mayer-Davis EJ, Petitti DB, Pihoker C, Dolan L & Dabelea DM. (2008). Prevalence and determinants of elevated apolipoprotein B and dense low-density lipoprotein in youths with type 1 and type 2 diabetes. J Clin Endocrinol Metab.; 93: 735-42

Austin MA, King MC, Vranizan KM & Krauss RM. (1990). Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation; 82, 495-506.

Bagdade JD & Subbaiah PV. (1989). Whole-plasma and high-density lipoprotein subfraction surface lipid composition in IDDM men. Diabetes; 38: 1226-30.
Bagdade JD, Ritter MC & Subbaiah PV. (1991a). Accelerated cholesteryl ester transfer in plasma of patients with insulin dependent diabetes mellitus. *Eur J Clin Invest*, 21, 161-167.

Bagdade JD, Helve E & Taskinen MR. (1991b). Effects of continuous insulin infusion therapy on lipoprotein surface and core lipid composition in insulin-dependent diabetes mellitus. *Metabolism*; 40: 445-9.

Bagdade JD, Dunn FL, Eckel RH & Ritter MC. (1994). Intraperitoneal insulin therapy corrects abnormalities in cholesteryl ester transfer and lipoprotein lipase activities in insulin-dependent diabetes mellitus. *Arterioscler Thromb*; 14: 1933-9.

Bagdade JD & Dunn FL. (1996). Improved lipoprotein surface and core lipid composition following intraperitoneal insulin delivery in insulin-dependent diabetes mellitus. *Diabetes Metab*; 22: 420-6.

Bagdade JD, Ritter MC, Kitabchi AE, Huss E, Thistlethwaite R, Gabfr O et al. (1996). Differing effects of pancreas-kidney transplantation with systemic versus portal venous drainage on cholesteryl ester transfer in IDDM subjects. *Diabetes Care*; 19:1108-12.

Boemi M, Leviev I, Sirolla C, Pieri C, Marra M & James RW. (2001). Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives; influence on the ability of HDL to protect LDL from oxidation. *Atherosclerosis*; 155: 229-35.

Brunzell JD, Schwartz RS, Eckel RH & Goldberg AP. (1981). Insulin and adipose tissue lipoprotein lipase activity in humans. *Int J Obes*; 5: 685-94.

Caixàs A, Ordóñez-Llanos J, de Leiva A, Payés A, Homs R & Pérez A. (1997). Optimization of glycemic control by insulin therapy decreases the proportion of small dense LDL particles in diabetic patients. *Diabetes*; 46: 1207-13.

Chait A, Bierman EL & Albers JJ. (1979). Low-density lipoprotein receptor activity in cultured human skin fibroblasts. Mechanism of insulin-induced stimulation. *J Clin Invest*; 64:1309-19.

Chang CK, Tso TK, Snook JT, Huang YS, Lozano RA & Zipf WB. (2001). Cholesteryl ester transfer and cholesteryl esterification in type 1 diabetes: relationships with plasma glucose. *Acta Diabetol*, 38: 37-42.

Chapman MJ, Guerin M & Bruckert E. (1998). Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches. *Eur Heart J*; 19 (Suppl A): A24-30.

Colhoun HM, Scheek LM, Rubens MB, Van Gent T, Underwood SR, Fuller JH et al. (2001). Lipid transfer protein activities in type 1 diabetic patients without renal failure and nondiabetic control subjects and their association with coronary artery calcification. *Diabetes*; 50: 652-9.

Dashti N, Wolfbauer G. (1987). Secretion of lipids, apolipoproteins, and lipoproteins by human hepatoma cell line, HepG2: effects of oleic acid and insulin. *J Lipid Res*; 28: 423-36.

de Castro SH, Castro-Faria-Neto HC & Gomes MB. (2005). Association of postprandial hyperglycemia with in vitro LDL oxidation in non-smoking patients with type 1 diabetes--a cross-sectional study. *Rev Diabet Stud*; 2: 157-64.
Dullaart RP, Dikkeschei LD & Doorenbos H. (1989a). Alterations in serum lipids and apolipoproteins in male type 1 (insulin-dependent) diabetic patients with microalbuminuria. *Diabetologia*; 32: 685-9.

Dullaart RP, Groener JE, Dikkeschei LD, Erkelens DW & Doorenbos H. (1989b). Increased cholesteryl ester transfer activity in complicated type 1 (insulin-dependent) diabetes mellitus--its relationship with serum lipids. *Diabetologia*; 32:14-9.

Dullaart RP, Groener JE, Dikkeschei BD, Erkelens DW & Doorenbos H. (1991). Elevated cholesteryl ester transfer protein activity in IDDM men who smoke. Possible factor for unfavorable lipoprotein profile. *Diabetes Care*; 14: 338-41.

Dullaart RP. (1995). Plasma lipoprotein abnormalities in type 1 (insulin-dependent) diabetes mellitus. *Neth J Med*; 46: 44-54.

Dunn FL. (1992). Plasma lipid and lipoprotein disorders in IDDM. *Diabetes*, 41 (Suppl 2): 102-6.

Duvillard L, Florentin E, Baillot-Rudoni S, Lalanne-Mistrich ML, Brun-Pacaud A, Petit JM, Brun JM, Gambert P & Vergès B (2005). Comparison of apolipoprotein B100 metabolism between continuous subcutaneous and intraperitoneal insulin therapy in type 1 diabetes. *J Clin Endocrinol Metab*; 90: 5761-4.

Duvillard L, Florentin E, Baillot-Rudoni S, Lalanne-Mistrich ML, Brun-Pacaud A, Petit JM, Brun JM, Gambert P & Vergès B. (2007). No change in apolipoprotein AI metabolism when subcutaneous insulin infusion is replaced by intraperitoneal insulin infusion in type 1 diabetic patients. *Atherosclerosis*; 194: 342-7.

Eckel RH, Albers JJ, Cheung MC, Wahl PW, Lindgren FT & Bierman EL. (1981). High density lipoprotein composition in insulin-dependent diabetes mellitus. *Diabetes*; 30: 132-8.

Edge JA, James T & Shine B. (2008). Longitudinal screening of serum lipids in children and adolescents with Type 1 diabetes in a UK clinic population. *Diabet Med.*; 25: 942-8.

Ferretti G, Bacchetti T, Busni D, Rabini RA & Curatola G. (2004). Protective effect of paraoxonase activity in high-density lipoproteins against erythrocyte membranes peroxidation: a comparison between healthy subjects and type 1 diabetic patients. *J Clin Endocrinol Metab*; 89: 2957-62.

Fievret C, Theret N, Shojaee N, Duchateau P, Castro G, Ailhaud G et al. (1992). Apolipoprotein A-I-containing particles and reverse cholesterol transport in IDDM. *Diabetes*; 41 (Suppl 2): 81-5.

Fried SK, Russell CD, Grauso NL & Brolin RE. (1993). Lipoprotein lipase regulation by insulin and glucocorticoid in subcutaneous and omental adipose tissues of obese women and men. *J Clin Invest*; 92: 2191-8.

Graulsund J, Jørgensen TM, Nybo M, Green A, Rasmussen LM & Sjølie AK. (2010). Risk factors for mortality and ischemic heart disease in patients with long-term type 1 diabetes. *J Diabetes Complications*; 24: 223-8.

Guy J, Ogden L, Wadwa RP, Hamman RF, Mayer-Davis EJ, Liese AD et al. (2009). Lipid and lipoprotein profiles in youth with and without type 1 diabetes: the SEARCH for Diabetes in Youth case-control study. *Diabetes Care*; 32: 416-20.
Hoeldtke RD, Bryner KD, Corum LL, Hobbs GR & Van Dyke K. (2009). Lipid peroxidation in early type 1 diabetes mellitus is unassociated with oxidative damage to DNA. *Metabolism*; 58: 731-4.

James RW & Pometta D. (1990). Differences in lipoprotein subfraction composition and distribution between type I diabetic men and control subjects. *Diabetes*; 39: 1158-64.

Jay RH, Jones SL, Hill CE, Richmond W, Viberti GC, Rampling MW et al. (1991). Blood rheology and cardiovascular risk factors in type 1 diabetes: relationship with microalbuminuria. *Diabet Med*; 8: 662-7.

Jensen T, Borch-Johnsen K, Kofoed-Enevoldsen A & Deckert T. (1987). Coronary heart disease in young type 1 (insulin-dependent) diabetic patients with and without diabetic nephropathy: incidence and risk factors. *Diabetologia*; 30:144-8.

Jian B, de la Llera-Moya M, Ji Y, Wang N, Phillips MC, Swaney JB et al. (1998). Scavenger receptor class B type I as a mediator of cellular cholesterol efflux to lipoproteins and phospholipid acceptors. *J Biol Chem*; 273:5599-606.

Jones SL, Close CF, Mattock MB, Jarrett RJ, Keen H & Viberti GC. (1989). Plasma lipid and coagulation factor concentrations in insulin dependent diabetics with microalbuminuria. *BMJ*; 298: 487-90.

Kahri J, Groop PH, Viberti G, Elliott T & Taskinen MR. (1993). Regulation of apolipoprotein A-I-containing lipoproteins in IDDM. *Diabetes*; 42:1281-8.

Klein RL, Lyons TJ & Lopes-Virella MF. (1989). Interaction of very-low-density lipoprotein isolated from type I (insulin-dependent) diabetic subjects with human monocyte-derived macrophages. *Metabolism*; 38:1108-14.

Kuksis A, Myher JJ, Geher K, Jones GJ, Breckenridge WC, Feather T et al. (1982). Decreased plasma phosphatidylcholine/free cholesterol ratio as an indicator of risk for ischemic vascular disease. *Arteriosclerosis*; 2: 296-302.

Lagrost L, Desrumaux C, Masson D, Deckert V & Gambert P. (1998). Structure and function of the plasma phospholipid transfer protein. *Curr Opin Lipidol*; 9: 203-9.

Lagrost L. (1994). Regulation of cholesteryl ester transfer protein (CETP) activity: review of in vitro and in vivo studies. *Biochim Biophys Acta*; 1215: 209-36.

Lahdenperä S, Groop PH, Tilly-Kiesi M, Kuusi T, Elliott TG, Viberti GC et al. (1994). LDL subclasses in IDDM patients: relation to diabetic nephropathy. *Diabetologia*; 37: 681-8.

Lewis GF, Uffelman KD, Szeto LW, Weller B & Steiner G. (1993). Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL apo B production in normal weight and obese individuals. *Diabetes*; 42: 833-42.

Libby P, Nathan DM, Abraham K, Brunzell JD, Fradkin JE, Haffner SM, Hsueh W, Rewers M, Roberts BT, Savage PJ, Skarlatos S, Wassef M, Rabadán-Diehl C & National Heart, Lung, and Blood Institute; National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus. (2005). Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus. *Circulation*; 111: 3489-93.
Link JJ, Rohatgi & de Lemos JA. (2007). HDL cholesterol: physiology, pathophysiology, and management. *Curr Probl Cardiol*; 32: 268-314.

Lopes-Virella MF, Hunt KJ, Baker NL, Lachin J, Nathan DM, Virella G & Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. (2011). Levels of oxidized LDL and advanced glycation end products-modified LDL in circulating immune complexes are strongly associated with increased levels of carotid intima-media thickness and its progression in type 1 diabetes. *Diabetes*; 60: 582-9.

Maahs DM, Ogden LG, Dabelea D, Snell-Bergeon JK, Daniels SR, Hamman RF & Rewers M. (2010). Association of glycaemia with lipids in adults with type 1 diabetes: modification by dyslipidaemia medication. *Diabetologia*; 53: 2518-25.

Maahs DM, Nadeau K, Snell-Bergeon JK, Schauer I, Bergman B, West NA, Rewers M, Daniels SR, Ogden LG, Hamman RF & Dabelea D. (2011). Association of insulin sensitivity to lipids across the lifespan in people with Type 1 diabetes. *Diabet Med.*; 28:148-55.

Malmström R, Packard CJ, Caslake M, Bedford D, Stewart P, Yki-Jarvinen H et al. (1998). Effects of insulin and acipimox on VLDL1 and VLDL2 apolipoprotein B production in normal subjects. *Diabetes*; 47: 779-87.

Marcovecchio ML, Dalton RN, Prevost AT, Acerini CL, Barrett TG, Cooper JD et al. (2009). Prevalence of Abnormal Lipid Profiles and the Relationship with the Development of Microalbuminuria in Adolescents with Type 1 Diabetes. *Diabetes Care*; 32: 658-663.

Mattock MB, Cronin N, Cavallone-Perin P, Idzior-Walus B, Penno G, Bandinelli S et al. (2001). EURODIAB IDDM Complications Study. Plasma lipids and urinary albumin excretion rate in Type 1 diabetes mellitus: the EURODIAB IDDM Complications Study. *Diabet Med*; 18: 59-67.

Mazzone T, Foster D & Chait A. (1984). In vivo stimulation of low-density lipoprotein degradation by insulin. *Diabetes*; 33: 333-8.

Nikkilä EA & Kekki M. (1973). Plasma triglyceride transport kinetics in diabetes mellitus. *Metabolism*; 22:1-22.

Nikkilä EA, Huttunen JK & Ehnholm C. (1977). Postheparin plasma lipoprotein lipase and hepatic lipase in diabetes mellitus. Relationship to plasma triglyceride metabolism. *Diabetes*; 26:11-21.

Olofsson SO, Stillemark-Blinton P & Asp L. (2000). Intracellular assembly of VLDL: two major steps in separate cell compartments. *Trends Cardiovasc Med*; 10: 338-45.

Oram JF & Lawn RM. ABCA1. (2001). The gatekeeper for eliminating excess tissue cholesterol. *J Lipid Res*; 42:1173-9.

Perségol L, Foissac M, Lagrost L, Athias A, Gambert P, Vergès B & Duvillard L. (2007). HDL particles from type 1 diabetic patients are unable to reverse the inhibitory effect of oxidised LDL on endothelium-dependent vasorelaxation. *Diabetologia*; 50: 2384-7.

Pruneta V, Pulcini T, Lalanne F, Marcais C, Berthezène F, Ponsin G et al. (1999). VLDL-bound lipoprotein lipase facilitates the cholesteryl ester transfer protein-mediated transfer of cholesteryl esters from HDL to VLDL. *J Lipid Res*; 40:2333-9.
Purnell JQ, Dev RK, Steffes MW, Cleary PA, Palmer JP, Hirsch IB, Hokanson JE & Brunzell JD. (2003). Relationship of family history of type 2 diabetes, hypoglycemia, and autoantibodies to weight gain and lipids with intensive and conventional therapy in the Diabetes Control and Complications Trial. *Diabetes*; 52: 2623-9.

Ritter MC & Bagdade JD. (1994). Contribution of glycaemic control, endogenous lipoproteins and cholesteryl ester transfer protein to accelerated cholesteryl ester transfer in IDDM. *Eur J Clin Invest*; 24: 607-14.

Rivellese A, Riccardi G, Romano G, Giacco R, Patti L, Marotta G et al. (1988). Presence of very low density lipoprotein compositional abnormalities in type 1 (insulin-dependent) diabetic patients; effects of blood glucose optimisation. *Diabetologia*; 31: 884-8.

Ruotolo G, Parlavacchia M, Taskinen MR, Galimberti G, Zoppo A, Le NA et al. (1994). Normalization of lipoprotein composition by intraperitoneal insulin in IDDM. Role of increased hepatic lipase activity. *Diabetes Care*; 17: 6-12.

Sammett D & Tall AR. (1985). Mechanisms of enhancement of cholesteryl ester transfer protein activity by lipolysis. *J Biol Chem*; 260: 6687-97.

Schwab KO, Doerfer J, Naeke A, Rohrer T, Wiemann D, Marg W, Hofer SE, Holl RW & German/Austrian Pediatric DPV Initiative. (2009). Influence of food intake, age, gender, HbA1c, and BMI levels on plasma cholesterol in 29,979 children and adolescents with type 1 diabetes—reference data from the German diabetes documentation and quality management system (DPV). *Pediatr Diabetes*; 10: 184-92.

Selam JL, Kashyap M, Alberti KG, Lozano J, Hanna M, Turner D et al. (1989). Comparison of intraperitoneal and subcutaneous insulin administration on lipids, apolipoproteins, fuel metabolites, and hormones in type I diabetes mellitus. *Metabolism*; 38: 908-12.

Skyrme-Jones RA, O’Brien RC, Luo M & Meredith IT. (2000). Endothelial vasodilator function is related to low-density lipoprotein particle size and low-density lipoprotein vitamin E content in type 1 diabetes. *J Am Coll Cardiol*; 35: 292-9.

Soedamah-Muthu SS, Chaturvedi N, Toeller M, Ferriss B, Reboldi P, Michel G, Manes C, Fuller JH & EURODIAB Prospective Complications Study Group. (2004). Risk factors for coronary heart disease in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study. *Diabetes Care*; 27: 530-7.

Steinbrecher UP & Witztum JL. (1984). Glucosylation of low-density lipoproteins to an extent comparable to that seen in diabetes slows their catabolism. *Diabetes*; 33:130-4.

Taskinen MR. (1987). Lipoprotein lipase in diabetes. *Diabetes Metab Rev*; 3:551-70.

Taskinen MR. (1992). Quantitative and qualitative lipoprotein abnormalities in diabetes mellitus. *Diabetes*; 41 (Suppl 2):12-7.

The DCCT Research Group. (1992). Lipid and lipoprotein levels in patients with IDDM diabetes control and complication. Trial experience. *Diabetes Care*; 15: 886-94.

Thomas MC, Rosengård-Bärlund M, Mills V, Rönnback M, Thomas S, Forsblom C et al. (2006). Serum lipids and the progression of nephropathy in type 1 diabetes. *Diabetes Care*; 29: 317-22.
Tribble DL, Holl LG, Wood PD & Krauss RM. (1992). Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. *Atherosclerosis*; 93: 189-99.

Vakkilainen J, Makimattila S, Seppala-Lindroos A, Vehkavaara S, Lahdenpera S, Groop PH et al. (2000). Endothelial dysfunction in men with small LDL particles. *Circulation*; 102: 716-21.

Vergès B. (2001). Insulin sensitivity and lipids. *Diabetes Metab*; 27: 223-7.

Weidman SW, Ragland JB, Fisher JN Jr, Kitabchi AE & Sabesin SMJ. (1982). Effects of insulin on plasma lipoproteins in diabetic ketoacidosis: evidence for a change in high density lipoprotein composition during treatment. *J Lipid Res*; 23: 171-82.

Winocour PH, Durrington PN, Ishola M & Anderson DC. (1986). Lipoprotein abnormalities in insulin-dependent diabetes mellitus. *Lancet*; 1: 1176-8.

Witztum JL, Mahoney EM, Branks MJ, Fisher M, Elam R & Steinberg D. (1982). Nonenzymatic glucosylation of low-density lipoprotein alters its biologic activity. *Diabetes*; 31: 283-91.
This book is intended as an overview of recent progress in type 1 diabetes research worldwide, with a focus on different research areas relevant to this disease. These include: diabetes mellitus and complications, psychological aspects of diabetes, perspectives of diabetes pathogenesis, identification and monitoring of diabetes mellitus, and alternative treatments for diabetes. In preparing this book, leading investigators from several countries in these five different categories were invited to contribute a chapter to this book. We have striven for a coherent presentation of concepts based on experiments and observation from the authors own research and from existing published reports. Therefore, the materials presented in this book are expected to be up to date in each research area. While there is no doubt that this book may have omitted some important findings in diabetes field, we hope the information included in this book will be useful for both basic science and clinical investigators. We also hope that diabetes patients and their family will benefit from reading the chapters in this book.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:

Bruno Vergès (2011). Lipid Disorders in Type 1 Diabetes, Type 1 Diabetes - Complications, Pathogenesis, and Alternative Treatments, Prof. Chih-Pin Liu (Ed.), ISBN: 978-953-307-756-7, InTech, Available from: http://www.intechopen.com/books/type-1-diabetes-complications-pathogenesis-and-alternative-treatments/lipid-disorders-in-type-1-diabetes